Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmos’ dexanabinol (correction)

Executive Summary

Pharmos' Phase III trial for its cannabinoid dexanabinal in traumatic brain injury has completed projected enrollment of about 860 patients in the U.S. and other countries; results are expected by year-end. FDA placed the NMDA antagonist on fast track status in September 2003. Dexanabinol has never been in clinical development for Parkinson's disease or Alzheimer's disease as suggested in the 1March 22 issue of "The Pink Sheet" (p. 38)...

You may also be interested in...



Novartis, Cephalon Disease-Modifying Parkinson’s Drugs Near Late Stages

Novartis' and Cephalon's disease-modifying Parkinson's disease agents are approaching the final stages of development, with at least one pivotal trial slated to begin in 2004

J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints

If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.

Woodcock To Be Acting US FDA Commissioner; Sharfstein Tops Biden's List Of Candidates For Post

Agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give Biden team cushion to confirm a permanent leader of whom a top contender is former senior FDA staffer Joshua Sharfstein, a proponent of drug reforms that may irk manufacturers.

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel